Latest Conference Coverage

Formulating the Right Combination of Acoustic Metrics to Quantify Cognitive Impairment: Alvaro Pascual-Leone, MD, PhD

The chief medical officer and cofounder of Linus Health provided background on the reasoning for the measures used in a new machine learning algorithm that classifies cognitive status. [WATCH TIME: 3 minutes]

AAIC Expert Insight: Can Alzheimer Disease Be Treated With a Single-Target Approach?

During a Focused Topic Session at the 2022 Alzheimer’s Association International Conference, NeurologyLive® inquired with a panel of experts about the possibility of exploring a combination approach to Alzheimer disease as the future of treatment.

Cognition and Fall Risk Improved in Alzheimer Disease Following Exercise Program

All severities of Alzheimer disease showed statistically significant benefits from the exercise program relative to controls, with more mild groups demonstrating the most improvement.

Crenezumab Fails to Meet Primary End Points in API ADAD Colombia Trial

The monoclonal antibody that preferentially targets Aß oligomers failed to meet either of its coprimary end points—despite favorable results over the placebo group—in individuals who were unimpaired but at risk for AD.

Rare Missense Variant of APOE Shows Increased Risk of Alzheimer Disease in African Ancestry

Using several large-scale cohorts, findings showed that cumulative incidence of Alzheimer disease grows faster with age in R145C variant carriers compared with noncarriers, contradicting prior research results.

Using Machine Learning, Speech Production to Quantify Mild Cognitive Impairment: Alvaro Pascual-Leone, MD, PhD

The medical director of the Deanna and Sidney Wolk Center for Memory Health provided background on his new study using multimodal digital biomarkers to classify patients with mild cognitive impairment. [WATCH TIME: 5 minutes]

Post-COVID Cognitive and Functional Impairments Predicted by Anosmia, Not Infection Severity

Across the cohort, 11.6% of patients had impairments in memory, attention, and executive function; however, cognitive status was influenced by severity of anosmia, or loss of taste and smell.

Discrimination Plays Role In Late-Life Cognitive Inequalities

Non-White participants over 90 years of age who reported a mean of 4 discrimination experiences had significantly worse baseline semantic memory compared with those who reported little/no discrimination.

Complexities With SMN2 Copies in Spinal Muscular Atrophy: Basil Darras, MD

The associate neurologist-in-chief at Boston Children’s Hospital discussed the 4-copy conundrum and whether treatment decisions differ based on SMN2 copies for patients with spinal muscular atrophy. [WATCH TIME: 2 minutes]

Positive Life Change During Pandemic Linked to Fewer Cognitive Symptoms Among Latin American Elderly

A cohort of more than 2000 older Latin American individuals reported a significant difference in cognitive symptoms when they underwent a positive life change during the early phase of the COVID-19 pandemic.

ICU Hospitalization Associated With Significantly Increased Risk of Dementia

As hospitalizations remain high throughout the COVID-19 pandemic, new data suggests that ICU hospitalization is associated with increased risk of Alzheimer disease and all-type dementia.

NeurologyLive® Brain Games: July 31, 2022

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Alzheimer's Association.

Assessing Treatment Options and Improving Utilization for Spinal Muscular Atrophy: Basil Darras, MD

The associate neurologist-in-chief at Boston Children’s Hospital provided insight on the treatment decisions clinicians make for patients with SMA and the challenges with improving optimization. [WATCH TIME: 3 minutes]

Complexities of Presymptomatic Spinal Muscular Atrophy: Basil Darras, MD

The associate neurologist-in-chief at Boston Children’s Hospital discussed the importance of defining and acting on spinal muscular atrophy in its presymptomatic stages. [WATCH TIME: 4 minutes]

Institutional Perspectives in Neurology, Chaired by Annette Okai, MD

Chaired by Annette Okai, MD, of North Texas Institute of Neurology & Headache, the presentations also feature Fernando Cuascut, MD, MPH, of Baylor College of Medicine; and Lauren Tardo, MD, and Rebecca Romero, MD, of UT Southwestern Medical Center. [WATCH TIME: 1 hour, 18 minutes]

NeurologyLive® Brain Games: July 24, 2022

The Treatment of Status Migrainosus in Emergency Care Settings: Matthew Robbins, MD

The neurologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital offered his insight into the state of treatment for status migrainosus and whether or not the new migraine medications can help improve care. [WATCH TIME: 2 minutes]

Learning From Patients and Looking to the Future of Movement Disorder Care

Jill Farmer, DO, MPH, director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute, spoke at length about the recent ATMRD Congress, the state of care for movement disorders, and her hopes for the horizon of therapy and treatment.

The Need for More Time in Movement Disorder Care: Temitope Lawal, MD

The neurologist and movement disorders fellow at University Hospitals Cleveland Medical Center spoke about the need for clinicians to have more time with patients in clinical practice, particularly with those with chronic diseases. [WATCH TIME: 2 minutes]

NeurologyLive® Brain Games: July 17, 2022

Drawing From Experience When Treating Parkinson Disease: Temitope Lawal, MD

The neurologist and movement disorders fellow at University Hospitals Cleveland Medical Center spoke about how his experience as a caregiver shapes his perspective as a doctor in care for those with movement disorders. [WATCH TIME: 3 minutes]

State of Migraine Care and Therapeutics: Richard B. Lipton, MD

The director of the Montefiore Headache Center provided an overview of the recent advances in migraine medications and how it has translated to improved care. [WATCH TIME: 2 minutes]

Working With Interdisciplinary Teams in Movement Disorders: Temitope Lawal, MD

The neurologist and movement disorders fellow at University Hospitals Cleveland Medical Center shared his experiences engaging with a diverse community of clinicians at the ATMRD Congress and in clinical practice. [WATCH TIME: 2 minutes]

Advantages in Adding Intranasal Zavagepant to the Migraine Treatment Landscape: Richard B. Lipton, MD

The director of the Montefiore Headache Center provided commentary on how analyses presented at AHS 2022 further support the benefits intranasal zavagepant bring to the migraine treatment landscape. [WATCH TIME: 5 minutes]

Efficacy, Safety of Rimegepant When Used Both as Preventively and As-Need: Richard B. Lipton, MD

The director of the Montefiore Headache Center provided insight on an open-label study presented at AHS 2022 that highlighted rimegepant’s (Nurtec ODT; Biohaven) impact both as a preventative and acute medication. [WATCH TIME: 5 minutes]

NeurologyLive® Brain Games: July 10, 2022

Understanding the Impact of MiCOAS Qualitative Study: Richard B. Lipton, MD

The director of the Montefiore Headache Center discussed the intuitiveness and advantages the Migraine Clinical Outcome Assessment System, or MiCOAS, grant provides to clinical trials and patients with migraine. [WATCH TIME: 5 minutes]

Understanding Individual Risks, Improving Trial Designs for Sleep Disorders in Alzheimer Disease

Ruth Benca, MD, PhD, a professor and the chair of Psychiatry & Human Behavior at Wake Forest School of Medicine, provided insight on the age- and sex-related differences in sleep disorders, and the needed research on the effects of therapeutics in older populations.

Advocating for Patients With Migraine Through Research Initiatives: Serena L. Orr, MD, MSc

The pediatric neurologist and headache specialist at the University of Calgary and Alberta Children’s Hospital spoke about the need for improved funding and research efforts for the migraine population. [WATCH TIME: 5 minutes]

Cure CMD: Benefits of the Biennial SciFam Conference

Rachel Alvarez and Gustavo Dziewczapolski, PhD, of Cure CMD spoke about the benefits of attending the biennial Scientific & Family Conference to learn more about congenital muscle diseases and interact with the patient community.